Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...

A study found that hospital sink drains harbor dangerous bacteria, including antibiotic-resistant strains. Despite thorough ...

California Gov. Gavin Newsom and state legislators in Sacramento seem to agree: Prescription drug prices are too high. But ...

A small study confirms observations what users have observed: the medications reduce their cravings for alcohol.

As prescription drug prices continue to spiral and federal efforts to control them stall, state lawmakers are focusing on ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

A trio of high-octane income stocks -- sporting an average yield of 6.65% -- can fatten investors' pocketbooks in 2025 (and ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...